Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Oncolytic Viruses | 30 | 2024 | 344 | 10.120 |
Why?
|
Oncolytic Virotherapy | 35 | 2024 | 520 | 9.260 |
Why?
|
Immunotherapy | 84 | 2024 | 4746 | 6.780 |
Why?
|
Melanoma | 73 | 2024 | 5695 | 6.700 |
Why?
|
Cancer Vaccines | 54 | 2018 | 1042 | 6.150 |
Why?
|
Interleukin-2 | 28 | 2024 | 1894 | 4.130 |
Why?
|
Skin Neoplasms | 54 | 2024 | 5836 | 4.050 |
Why?
|
Carcinoma, Merkel Cell | 15 | 2024 | 328 | 3.670 |
Why?
|
Vaccinia virus | 20 | 2009 | 328 | 2.860 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 13 | 2019 | 890 | 2.430 |
Why?
|
Carcinoembryonic Antigen | 20 | 2011 | 336 | 2.280 |
Why?
|
Neoplasms | 56 | 2024 | 22344 | 2.070 |
Why?
|
Herpesvirus 1, Human | 13 | 2024 | 743 | 1.940 |
Why?
|
Carcinoma, Renal Cell | 20 | 2023 | 3186 | 1.810 |
Why?
|
Poxviridae | 9 | 2006 | 37 | 1.580 |
Why?
|
Antibodies, Monoclonal | 17 | 2019 | 9237 | 1.510 |
Why?
|
Kidney Neoplasms | 18 | 2023 | 4282 | 1.500 |
Why?
|
Vaccines, Synthetic | 17 | 2014 | 622 | 1.410 |
Why?
|
Antineoplastic Agents | 31 | 2021 | 13635 | 1.330 |
Why?
|
Molecular Targeted Therapy | 9 | 2021 | 2824 | 1.260 |
Why?
|
Simplexvirus | 7 | 2024 | 805 | 1.240 |
Why?
|
Injections, Intralesional | 15 | 2020 | 280 | 1.100 |
Why?
|
Neoplasm Metastasis | 25 | 2024 | 4887 | 1.040 |
Why?
|
T-Lymphocytes | 25 | 2021 | 10260 | 1.030 |
Why?
|
Biological Products | 6 | 2024 | 947 | 0.980 |
Why?
|
Genetic Vectors | 14 | 2019 | 3400 | 0.950 |
Why?
|
Viral Vaccines | 11 | 2008 | 596 | 0.890 |
Why?
|
Herpes Simplex | 4 | 2024 | 470 | 0.830 |
Why?
|
Interleukin-12 | 5 | 2024 | 581 | 0.750 |
Why?
|
Coxsackievirus Infections | 1 | 2021 | 45 | 0.740 |
Why?
|
Neoplasm Staging | 20 | 2023 | 11200 | 0.720 |
Why?
|
Antigens, Neoplasm | 17 | 2018 | 1996 | 0.710 |
Why?
|
Humans | 225 | 2024 | 766117 | 0.700 |
Why?
|
Melanoma, Experimental | 2 | 2016 | 555 | 0.690 |
Why?
|
Medical Oncology | 5 | 2020 | 2339 | 0.660 |
Why?
|
Lymphocyte Activation | 8 | 2018 | 5503 | 0.630 |
Why?
|
Thoracic Neoplasms | 1 | 2021 | 268 | 0.610 |
Why?
|
Pancreatic Neoplasms | 12 | 2016 | 5454 | 0.600 |
Why?
|
Adenocarcinoma | 16 | 2015 | 6363 | 0.580 |
Why?
|
Tumor Microenvironment | 16 | 2024 | 3942 | 0.550 |
Why?
|
Endpoint Determination | 2 | 2018 | 591 | 0.520 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 634 | 0.510 |
Why?
|
Animals | 73 | 2024 | 168800 | 0.500 |
Why?
|
Colorectal Neoplasms | 9 | 2018 | 6961 | 0.490 |
Why?
|
Vaccination | 10 | 2019 | 3431 | 0.480 |
Why?
|
T-Lymphocytes, Cytotoxic | 6 | 2018 | 1801 | 0.470 |
Why?
|
Fowlpox virus | 1 | 2014 | 21 | 0.460 |
Why?
|
Treatment Outcome | 38 | 2024 | 65219 | 0.450 |
Why?
|
Gold | 1 | 2017 | 480 | 0.440 |
Why?
|
Survival Analysis | 13 | 2020 | 10087 | 0.440 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11859 | 0.440 |
Why?
|
Chemokines, CC | 2 | 2005 | 285 | 0.430 |
Why?
|
Protein Kinase Inhibitors | 4 | 2018 | 5695 | 0.420 |
Why?
|
Head and Neck Neoplasms | 4 | 2024 | 2926 | 0.420 |
Why?
|
GPI-Linked Proteins | 1 | 2015 | 472 | 0.420 |
Why?
|
Carcinoma, Squamous Cell | 7 | 2023 | 4049 | 0.420 |
Why?
|
Caveolin 1 | 2 | 2014 | 255 | 0.420 |
Why?
|
Listeria monocytogenes | 1 | 2015 | 245 | 0.410 |
Why?
|
Antibodies, Neoplasm | 5 | 2011 | 282 | 0.410 |
Why?
|
Cranial Irradiation | 1 | 2015 | 384 | 0.410 |
Why?
|
Vaccines, DNA | 7 | 2012 | 279 | 0.410 |
Why?
|
4-1BB Ligand | 2 | 2009 | 28 | 0.400 |
Why?
|
Immunotherapy, Active | 2 | 2012 | 58 | 0.400 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2022 | 2054 | 0.400 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 988 | 0.390 |
Why?
|
Aged | 63 | 2024 | 171219 | 0.390 |
Why?
|
Chemokines | 3 | 2007 | 959 | 0.380 |
Why?
|
Albumins | 1 | 2014 | 578 | 0.380 |
Why?
|
Triamcinolone | 1 | 2011 | 68 | 0.380 |
Why?
|
Endothelial Cells | 2 | 2014 | 3586 | 0.370 |
Why?
|
Keloid | 1 | 2011 | 55 | 0.370 |
Why?
|
Dose-Response Relationship, Drug | 12 | 2019 | 10737 | 0.360 |
Why?
|
T-Lymphocytes, Regulatory | 8 | 2016 | 3112 | 0.360 |
Why?
|
Craniotomy | 1 | 2015 | 737 | 0.360 |
Why?
|
Immunity, Cellular | 4 | 2019 | 1557 | 0.360 |
Why?
|
Middle Aged | 65 | 2024 | 223083 | 0.360 |
Why?
|
Female | 92 | 2024 | 396233 | 0.350 |
Why?
|
Dendritic Cells | 10 | 2018 | 2747 | 0.350 |
Why?
|
Virus Replication | 6 | 2018 | 2458 | 0.350 |
Why?
|
Evidence-Based Medicine | 4 | 2019 | 3690 | 0.350 |
Why?
|
Male | 83 | 2024 | 363935 | 0.350 |
Why?
|
Clinical Trials as Topic | 17 | 2020 | 8038 | 0.340 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2014 | 4408 | 0.340 |
Why?
|
Computational Biology | 2 | 2020 | 3565 | 0.340 |
Why?
|
CD8-Positive T-Lymphocytes | 13 | 2024 | 4649 | 0.330 |
Why?
|
Pyrimidinones | 3 | 2022 | 384 | 0.320 |
Why?
|
Cyclophosphamide | 1 | 2015 | 2232 | 0.310 |
Why?
|
Autoimmunity | 4 | 2016 | 1354 | 0.310 |
Why?
|
Interleukins | 2 | 2016 | 789 | 0.310 |
Why?
|
Cytokines | 9 | 2024 | 7426 | 0.310 |
Why?
|
Receptors, Interleukin-2 | 3 | 2014 | 561 | 0.310 |
Why?
|
Immune System | 4 | 2006 | 799 | 0.300 |
Why?
|
Combined Modality Therapy | 11 | 2024 | 8525 | 0.290 |
Why?
|
Mice | 34 | 2024 | 81839 | 0.290 |
Why?
|
Aged, 80 and over | 26 | 2024 | 59515 | 0.290 |
Why?
|
Lymphocyte Depletion | 1 | 2009 | 606 | 0.290 |
Why?
|
Immunologic Factors | 4 | 2022 | 1592 | 0.280 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2016 | 733 | 0.270 |
Why?
|
Indoles | 2 | 2014 | 1833 | 0.260 |
Why?
|
Prostatic Neoplasms | 7 | 2015 | 11094 | 0.260 |
Why?
|
Poxviridae Infections | 1 | 2005 | 10 | 0.260 |
Why?
|
Tumor Necrosis Factors | 1 | 2006 | 109 | 0.260 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2015 | 1762 | 0.260 |
Why?
|
Radiosurgery | 1 | 2015 | 1328 | 0.250 |
Why?
|
Gene Expression Regulation, Viral | 2 | 2005 | 434 | 0.250 |
Why?
|
Vaccines, Attenuated | 1 | 2007 | 314 | 0.250 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3111 | 0.250 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3233 | 0.250 |
Why?
|
Prognosis | 19 | 2024 | 29912 | 0.250 |
Why?
|
Adjuvants, Immunologic | 6 | 2019 | 993 | 0.250 |
Why?
|
Fibronectins | 1 | 2009 | 721 | 0.250 |
Why?
|
Neoplasms, Basal Cell | 2 | 2022 | 30 | 0.240 |
Why?
|
Clinical Protocols | 4 | 2010 | 1437 | 0.240 |
Why?
|
Tumor Cells, Cultured | 8 | 2016 | 6102 | 0.240 |
Why?
|
Immunity, Mucosal | 1 | 2008 | 498 | 0.240 |
Why?
|
Biomedical Research | 1 | 2020 | 3458 | 0.240 |
Why?
|
Antibodies, Viral | 4 | 2024 | 3214 | 0.240 |
Why?
|
Practice Guidelines as Topic | 3 | 2020 | 7424 | 0.240 |
Why?
|
Salmonella typhimurium | 1 | 2007 | 348 | 0.230 |
Why?
|
Panniculitis | 1 | 2005 | 45 | 0.230 |
Why?
|
Facial Neoplasms | 1 | 2005 | 126 | 0.230 |
Why?
|
Kaplan-Meier Estimate | 6 | 2018 | 6506 | 0.230 |
Why?
|
Genetic Engineering | 2 | 2021 | 933 | 0.230 |
Why?
|
Adult | 46 | 2024 | 223139 | 0.230 |
Why?
|
Colonic Neoplasms | 8 | 2004 | 2532 | 0.230 |
Why?
|
Adenoviridae | 5 | 2019 | 1092 | 0.220 |
Why?
|
Sulfonamides | 1 | 2014 | 1980 | 0.220 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 4 | 2018 | 1105 | 0.220 |
Why?
|
Immunotherapy, Adoptive | 4 | 2009 | 1504 | 0.220 |
Why?
|
Flow Cytometry | 7 | 2009 | 5881 | 0.220 |
Why?
|
Tumor Escape | 4 | 2017 | 371 | 0.220 |
Why?
|
Mice, Inbred C57BL | 12 | 2024 | 22341 | 0.210 |
Why?
|
Cytotoxicity, Immunologic | 5 | 2018 | 1346 | 0.210 |
Why?
|
Models, Immunological | 2 | 2018 | 517 | 0.210 |
Why?
|
CD40 Ligand | 1 | 2004 | 528 | 0.210 |
Why?
|
Receptors, Chemokine | 2 | 2006 | 651 | 0.210 |
Why?
|
Drugs, Investigational | 1 | 2004 | 211 | 0.200 |
Why?
|
Lymphatic Metastasis | 4 | 2016 | 2890 | 0.200 |
Why?
|
Interferon-gamma | 4 | 2014 | 3159 | 0.200 |
Why?
|
Adrenal Cortex Hormones | 1 | 2011 | 1882 | 0.200 |
Why?
|
Carcinoma, Basal Cell | 2 | 2022 | 565 | 0.200 |
Why?
|
Ulcer | 2 | 2021 | 202 | 0.200 |
Why?
|
Liver Neoplasms | 7 | 2016 | 4352 | 0.200 |
Why?
|
Cell Proliferation | 8 | 2018 | 10433 | 0.200 |
Why?
|
Neovascularization, Pathologic | 3 | 2018 | 2627 | 0.190 |
Why?
|
Killer Cells, Natural | 5 | 2021 | 2206 | 0.190 |
Why?
|
Patient Selection | 7 | 2017 | 4249 | 0.190 |
Why?
|
Prostate-Specific Antigen | 4 | 2005 | 2463 | 0.190 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 2 | 2019 | 153 | 0.190 |
Why?
|
Interferon-alpha | 2 | 2011 | 909 | 0.190 |
Why?
|
Cell Polarity | 1 | 2005 | 636 | 0.190 |
Why?
|
Dengue Virus | 1 | 2023 | 204 | 0.190 |
Why?
|
H-2 Antigens | 1 | 2001 | 359 | 0.180 |
Why?
|
Purine-Nucleoside Phosphorylase | 1 | 2001 | 28 | 0.180 |
Why?
|
Genes, APC | 1 | 2001 | 144 | 0.180 |
Why?
|
Avipoxvirus | 1 | 2000 | 4 | 0.180 |
Why?
|
AIDS Vaccines | 2 | 2005 | 898 | 0.180 |
Why?
|
Time Factors | 13 | 2018 | 40108 | 0.180 |
Why?
|
Interleukin-10 | 3 | 2019 | 1181 | 0.180 |
Why?
|
Cell Death | 4 | 2023 | 1676 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2018 | 10380 | 0.180 |
Why?
|
Digestive System | 1 | 2002 | 244 | 0.180 |
Why?
|
Containment of Biohazards | 1 | 2020 | 39 | 0.180 |
Why?
|
Disease Models, Animal | 10 | 2024 | 18321 | 0.180 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 6 | 2012 | 3801 | 0.180 |
Why?
|
Cell Line, Tumor | 11 | 2024 | 17071 | 0.180 |
Why?
|
Disease-Free Survival | 5 | 2016 | 6840 | 0.180 |
Why?
|
Stromal Cells | 1 | 2006 | 1332 | 0.180 |
Why?
|
Lung Neoplasms | 8 | 2019 | 13483 | 0.180 |
Why?
|
Brain Neoplasms | 3 | 2024 | 9065 | 0.170 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2016 | 958 | 0.170 |
Why?
|
Gene Expression | 7 | 2018 | 7582 | 0.170 |
Why?
|
Polyomavirus Infections | 2 | 2024 | 193 | 0.170 |
Why?
|
Quality of Life | 3 | 2017 | 13468 | 0.170 |
Why?
|
Dengue | 1 | 2023 | 258 | 0.170 |
Why?
|
Congresses as Topic | 3 | 2021 | 811 | 0.170 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2017 | 637 | 0.170 |
Why?
|
HLA-A2 Antigen | 2 | 2014 | 207 | 0.170 |
Why?
|
Th1 Cells | 1 | 2005 | 1041 | 0.170 |
Why?
|
Mastectomy, Segmental | 1 | 2005 | 965 | 0.160 |
Why?
|
Neoplasm Invasiveness | 4 | 2021 | 3602 | 0.160 |
Why?
|
Antibody Formation | 4 | 2014 | 1392 | 0.160 |
Why?
|
Survival Rate | 5 | 2024 | 12827 | 0.160 |
Why?
|
Synthetic Biology | 1 | 2021 | 185 | 0.160 |
Why?
|
Telomerase | 1 | 2024 | 749 | 0.160 |
Why?
|
Mucin-1 | 3 | 2011 | 535 | 0.160 |
Why?
|
Cryosurgery | 1 | 2024 | 479 | 0.160 |
Why?
|
Uveal Neoplasms | 1 | 2002 | 343 | 0.160 |
Why?
|
Membrane Glycoproteins | 3 | 2009 | 3692 | 0.160 |
Why?
|
Biology | 1 | 2021 | 293 | 0.160 |
Why?
|
Radiotherapy | 1 | 2005 | 1491 | 0.150 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2020 | 324 | 0.150 |
Why?
|
Immunocompetence | 1 | 2018 | 138 | 0.150 |
Why?
|
Extracellular Matrix | 1 | 2006 | 1727 | 0.150 |
Why?
|
Newcastle disease virus | 1 | 2018 | 21 | 0.150 |
Why?
|
Research Report | 1 | 2021 | 367 | 0.150 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 5388 | 0.150 |
Why?
|
Remission Induction | 3 | 2022 | 2413 | 0.150 |
Why?
|
Mycobacterium avium Complex | 1 | 1998 | 66 | 0.150 |
Why?
|
Drug Industry | 1 | 2004 | 791 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2020 | 878 | 0.150 |
Why?
|
MART-1 Antigen | 2 | 2010 | 62 | 0.150 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2009 | 3501 | 0.150 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 1998 | 82 | 0.140 |
Why?
|
Intercellular Adhesion Molecule-1 | 3 | 2006 | 1131 | 0.140 |
Why?
|
Mutation | 7 | 2024 | 30209 | 0.140 |
Why?
|
Mice, Inbred BALB C | 7 | 2016 | 6215 | 0.140 |
Why?
|
Splenomegaly | 1 | 1998 | 191 | 0.140 |
Why?
|
Diagnostic Imaging | 2 | 2021 | 3530 | 0.140 |
Why?
|
Glutamine | 1 | 2020 | 575 | 0.140 |
Why?
|
Fecal Incontinence | 2 | 2010 | 246 | 0.140 |
Why?
|
Pyridones | 2 | 2022 | 817 | 0.140 |
Why?
|
Cells, Cultured | 5 | 2014 | 18967 | 0.140 |
Why?
|
Tumor Burden | 3 | 2021 | 1889 | 0.140 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2018 | 195 | 0.140 |
Why?
|
Thalidomide | 1 | 2002 | 886 | 0.140 |
Why?
|
Lymphocyte Subsets | 1 | 2018 | 313 | 0.140 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2018 | 252 | 0.140 |
Why?
|
Mice, Transgenic | 5 | 2011 | 9540 | 0.140 |
Why?
|
Ileal Neoplasms | 2 | 2011 | 20 | 0.130 |
Why?
|
Neoplasms, Experimental | 2 | 2014 | 1227 | 0.130 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2015 | 1777 | 0.130 |
Why?
|
Splenectomy | 1 | 1998 | 389 | 0.130 |
Why?
|
Pyrroles | 2 | 2011 | 1120 | 0.130 |
Why?
|
Cecal Diseases | 1 | 1996 | 49 | 0.130 |
Why?
|
Molecular Biology | 1 | 2020 | 573 | 0.130 |
Why?
|
Epitopes | 3 | 2014 | 2523 | 0.130 |
Why?
|
Immunity, Innate | 3 | 2018 | 3079 | 0.130 |
Why?
|
Adaptive Immunity | 2 | 2018 | 733 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1056 | 0.130 |
Why?
|
Splenic Neoplasms | 1 | 2016 | 97 | 0.130 |
Why?
|
Adrenal Gland Neoplasms | 2 | 2016 | 731 | 0.130 |
Why?
|
Neoplasm Proteins | 3 | 2018 | 3594 | 0.130 |
Why?
|
Disease Progression | 6 | 2024 | 13616 | 0.130 |
Why?
|
Stomach Neoplasms | 3 | 2018 | 1471 | 0.130 |
Why?
|
DNA Polymerase II | 1 | 2016 | 103 | 0.130 |
Why?
|
Chloroquine | 1 | 2017 | 276 | 0.130 |
Why?
|
Sequence Analysis, RNA | 2 | 2015 | 2039 | 0.130 |
Why?
|
Dermatitis | 1 | 2017 | 201 | 0.130 |
Why?
|
Disease Management | 2 | 2018 | 2531 | 0.120 |
Why?
|
Serine Endopeptidases | 1 | 2020 | 1027 | 0.120 |
Why?
|
Imidazoles | 5 | 2022 | 1169 | 0.120 |
Why?
|
Chemokine CCL21 | 2 | 2005 | 49 | 0.120 |
Why?
|
ADP Ribose Transferases | 1 | 2015 | 90 | 0.120 |
Why?
|
Neoadjuvant Therapy | 3 | 2022 | 2897 | 0.120 |
Why?
|
Neuralgia | 1 | 2021 | 627 | 0.120 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 101 | 0.120 |
Why?
|
Hydroxybutyrates | 1 | 2014 | 75 | 0.120 |
Why?
|
Receptors, Dopamine D2 | 1 | 2017 | 471 | 0.120 |
Why?
|
Drug Eruptions | 1 | 2017 | 334 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2017 | 9378 | 0.110 |
Why?
|
Caveolae | 1 | 2014 | 54 | 0.110 |
Why?
|
History, 21st Century | 1 | 2020 | 1574 | 0.110 |
Why?
|
Follow-Up Studies | 7 | 2024 | 39243 | 0.110 |
Why?
|
Microsatellite Instability | 1 | 2018 | 726 | 0.110 |
Why?
|
Orthomyxoviridae Infections | 1 | 2016 | 255 | 0.110 |
Why?
|
Electric Stimulation Therapy | 2 | 2010 | 635 | 0.110 |
Why?
|
Drug Therapy | 1 | 2017 | 504 | 0.110 |
Why?
|
Fatigue | 2 | 2018 | 1552 | 0.110 |
Why?
|
Antigens, Differentiation | 2 | 2007 | 920 | 0.110 |
Why?
|
Vaccines | 1 | 2002 | 840 | 0.110 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3604 | 0.110 |
Why?
|
Lumbosacral Plexus | 2 | 2010 | 53 | 0.110 |
Why?
|
Young Adult | 9 | 2018 | 59868 | 0.100 |
Why?
|
src-Family Kinases | 2 | 2014 | 539 | 0.100 |
Why?
|
Hypopigmentation | 1 | 2013 | 43 | 0.100 |
Why?
|
Societies, Medical | 4 | 2024 | 3955 | 0.100 |
Why?
|
Retrospective Studies | 14 | 2024 | 81565 | 0.100 |
Why?
|
Recombination, Genetic | 2 | 2002 | 1525 | 0.100 |
Why?
|
Multicenter Studies as Topic | 1 | 2017 | 1729 | 0.100 |
Why?
|
Angiogenesis Inhibitors | 1 | 2002 | 2046 | 0.100 |
Why?
|
Microscopy, Confocal | 2 | 2009 | 1967 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 2019 | 780 | 0.100 |
Why?
|
Signal Transduction | 5 | 2018 | 23605 | 0.100 |
Why?
|
Vitiligo | 1 | 2013 | 96 | 0.100 |
Why?
|
Transfection | 3 | 2013 | 5739 | 0.100 |
Why?
|
GTPase-Activating Proteins | 1 | 2015 | 465 | 0.100 |
Why?
|
Consensus | 2 | 2020 | 3202 | 0.100 |
Why?
|
Gene Expression Regulation | 3 | 2020 | 11906 | 0.100 |
Why?
|
Vaccines, Subunit | 2 | 2002 | 159 | 0.090 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2018 | 615 | 0.090 |
Why?
|
Prospective Studies | 8 | 2019 | 54812 | 0.090 |
Why?
|
Repressor Proteins | 2 | 2019 | 2974 | 0.090 |
Why?
|
Treatment Failure | 2 | 2009 | 2653 | 0.090 |
Why?
|
Leiomyoma | 1 | 1996 | 644 | 0.090 |
Why?
|
Lymph Nodes | 3 | 2016 | 3456 | 0.090 |
Why?
|
Mutant Proteins | 1 | 2013 | 487 | 0.090 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12529 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2003 | 2176 | 0.090 |
Why?
|
Oncogenes | 1 | 2016 | 1232 | 0.090 |
Why?
|
Deoxycytidine | 2 | 2011 | 886 | 0.090 |
Why?
|
Capillary Permeability | 1 | 2014 | 770 | 0.090 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2013 | 393 | 0.090 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2010 | 152 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2001 | 3722 | 0.090 |
Why?
|
Defective Viruses | 1 | 2010 | 89 | 0.090 |
Why?
|
Genes, p53 | 2 | 2003 | 711 | 0.090 |
Why?
|
Genes, Viral | 1 | 1991 | 654 | 0.090 |
Why?
|
Breast Neoplasms | 4 | 2013 | 21074 | 0.090 |
Why?
|
Drug Therapy, Combination | 2 | 2017 | 6309 | 0.080 |
Why?
|
Antigen-Presenting Cells | 2 | 2013 | 960 | 0.080 |
Why?
|
Gene Transfer Techniques | 2 | 2005 | 1206 | 0.080 |
Why?
|
Endocytosis | 1 | 2014 | 952 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2002 | 3684 | 0.080 |
Why?
|
DNA Primers | 1 | 2014 | 2824 | 0.080 |
Why?
|
Lymph Node Excision | 1 | 2016 | 1262 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2015 | 3796 | 0.080 |
Why?
|
Recombinant Proteins | 3 | 2016 | 6493 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1943 | 0.080 |
Why?
|
Research Design | 2 | 2019 | 6206 | 0.080 |
Why?
|
Forecasting | 2 | 2013 | 2936 | 0.080 |
Why?
|
Autophagy | 1 | 2017 | 1349 | 0.080 |
Why?
|
Genes, MHC Class I | 1 | 2009 | 236 | 0.080 |
Why?
|
Aniline Compounds | 1 | 2014 | 1078 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 1996 | 2271 | 0.080 |
Why?
|
Glioblastoma | 1 | 2024 | 3458 | 0.080 |
Why?
|
Cell Survival | 2 | 2018 | 5747 | 0.080 |
Why?
|
Immunity | 2 | 2023 | 1001 | 0.080 |
Why?
|
Blotting, Southern | 2 | 2004 | 772 | 0.080 |
Why?
|
Monitoring, Immunologic | 1 | 2009 | 99 | 0.080 |
Why?
|
SEER Program | 1 | 2013 | 1443 | 0.070 |
Why?
|
Adenomatous Polyps | 1 | 2009 | 109 | 0.070 |
Why?
|
Microscopy, Fluorescence, Multiphoton | 1 | 2009 | 265 | 0.070 |
Why?
|
Drug Design | 2 | 2006 | 1040 | 0.070 |
Why?
|
Insurance Coverage | 1 | 2019 | 1945 | 0.070 |
Why?
|
Apoptosis | 4 | 2006 | 9508 | 0.070 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2011 | 590 | 0.070 |
Why?
|
Polymerase Chain Reaction | 2 | 2014 | 6059 | 0.070 |
Why?
|
Adoptive Transfer | 2 | 2014 | 827 | 0.070 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2011 | 646 | 0.070 |
Why?
|
Kinetics | 2 | 2008 | 6273 | 0.070 |
Why?
|
Lymphocyte Count | 2 | 2007 | 791 | 0.070 |
Why?
|
Transduction, Genetic | 1 | 2010 | 898 | 0.070 |
Why?
|
Neuroblastoma | 1 | 2015 | 1263 | 0.070 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2008 | 219 | 0.070 |
Why?
|
Receptors, Cytokine | 1 | 2007 | 257 | 0.070 |
Why?
|
Endometrial Neoplasms | 1 | 2016 | 1379 | 0.070 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2012 | 1331 | 0.070 |
Why?
|
Antigen Presentation | 3 | 2018 | 1250 | 0.070 |
Why?
|
Gallbladder Neoplasms | 2 | 2011 | 190 | 0.070 |
Why?
|
Leucovorin | 1 | 2008 | 643 | 0.070 |
Why?
|
Cell Cycle | 1 | 2014 | 2920 | 0.070 |
Why?
|
Microscopy, Atomic Force | 1 | 2007 | 250 | 0.070 |
Why?
|
Antigens, CD | 2 | 2007 | 4025 | 0.060 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 439 | 0.060 |
Why?
|
rho-Associated Kinases | 1 | 2008 | 291 | 0.060 |
Why?
|
Leukocytes | 1 | 2014 | 2030 | 0.060 |
Why?
|
Carcinoma in Situ | 1 | 2011 | 777 | 0.060 |
Why?
|
Immunohistochemistry | 5 | 2011 | 11035 | 0.060 |
Why?
|
Cell Movement | 2 | 2009 | 5196 | 0.060 |
Why?
|
Cheek | 1 | 2005 | 65 | 0.060 |
Why?
|
HIV Infections | 3 | 2014 | 17535 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12061 | 0.060 |
Why?
|
Electrodes, Implanted | 1 | 2010 | 835 | 0.060 |
Why?
|
Antibodies | 2 | 2022 | 2415 | 0.060 |
Why?
|
Receptors, CCR5 | 1 | 2007 | 491 | 0.060 |
Why?
|
Models, Biological | 3 | 2007 | 9445 | 0.060 |
Why?
|
HCT116 Cells | 2 | 2018 | 399 | 0.060 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2010 | 329 | 0.060 |
Why?
|
Eligibility Determination | 1 | 2009 | 422 | 0.060 |
Why?
|
Uric Acid | 1 | 2011 | 809 | 0.060 |
Why?
|
DNA, Recombinant | 1 | 2005 | 455 | 0.060 |
Why?
|
Enterocolitis | 1 | 2006 | 107 | 0.060 |
Why?
|
Colonoscopy | 2 | 2008 | 1408 | 0.060 |
Why?
|
HLA-A Antigens | 1 | 2005 | 223 | 0.060 |
Why?
|
Bacterial Vaccines | 1 | 2007 | 400 | 0.060 |
Why?
|
Camptothecin | 1 | 2008 | 598 | 0.060 |
Why?
|
Adolescent | 11 | 2017 | 88819 | 0.060 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2011 | 1362 | 0.060 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2007 | 588 | 0.060 |
Why?
|
X-Rays | 1 | 2005 | 309 | 0.060 |
Why?
|
Injections, Subcutaneous | 1 | 2006 | 683 | 0.060 |
Why?
|
Models, Animal | 1 | 2010 | 2120 | 0.060 |
Why?
|
Cell Division | 2 | 2002 | 4466 | 0.060 |
Why?
|
Aluminum Hydroxide | 1 | 2023 | 55 | 0.060 |
Why?
|
Microinjections | 1 | 2004 | 319 | 0.050 |
Why?
|
Autoimmune Diseases | 1 | 2016 | 2249 | 0.050 |
Why?
|
Drug Approval | 2 | 2021 | 820 | 0.050 |
Why?
|
Phenotype | 4 | 2013 | 16716 | 0.050 |
Why?
|
Pyridines | 4 | 2018 | 2889 | 0.050 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 2005 | 379 | 0.050 |
Why?
|
Pandemics | 2 | 2020 | 8725 | 0.050 |
Why?
|
Fluorouracil | 1 | 2008 | 1648 | 0.050 |
Why?
|
United States | 8 | 2024 | 72920 | 0.050 |
Why?
|
Consent Forms | 1 | 2003 | 55 | 0.050 |
Why?
|
Up-Regulation | 2 | 2009 | 4133 | 0.050 |
Why?
|
Base Sequence | 1 | 2014 | 12405 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2015 | 2559 | 0.050 |
Why?
|
Thyroid Neoplasms | 1 | 2016 | 2354 | 0.050 |
Why?
|
Goats | 1 | 2022 | 166 | 0.050 |
Why?
|
Herpesvirus 2, Human | 1 | 2024 | 191 | 0.050 |
Why?
|
Injections, Intravenous | 1 | 2005 | 1376 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 5336 | 0.050 |
Why?
|
Viruses | 1 | 2006 | 371 | 0.050 |
Why?
|
Mice, Nude | 2 | 2019 | 3610 | 0.050 |
Why?
|
Incidence | 3 | 2017 | 21513 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2013 | 8612 | 0.050 |
Why?
|
Drug Compounding | 1 | 2003 | 236 | 0.050 |
Why?
|
Hematuria | 1 | 2003 | 232 | 0.050 |
Why?
|
Cluster Analysis | 1 | 2009 | 2718 | 0.050 |
Why?
|
Parotid Gland | 1 | 2023 | 178 | 0.050 |
Why?
|
Lac Operon | 1 | 2002 | 237 | 0.050 |
Why?
|
Inflammation | 4 | 2020 | 10860 | 0.050 |
Why?
|
Cell Line | 3 | 2004 | 15546 | 0.050 |
Why?
|
Deoxyguanine Nucleotides | 1 | 2001 | 22 | 0.050 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2004 | 657 | 0.050 |
Why?
|
Purine Nucleosides | 1 | 2001 | 30 | 0.050 |
Why?
|
Glycosylphosphatidylinositols | 1 | 2001 | 83 | 0.050 |
Why?
|
Tumor Virus Infections | 1 | 2024 | 438 | 0.050 |
Why?
|
Caveolins | 1 | 2001 | 102 | 0.050 |
Why?
|
T-Lymphocyte Subsets | 2 | 2016 | 1814 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 4565 | 0.050 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2021 | 95 | 0.050 |
Why?
|
Gastrointestinal Tract | 1 | 2007 | 834 | 0.050 |
Why?
|
Substrate Specificity | 1 | 2005 | 1751 | 0.040 |
Why?
|
Pyrimidines | 3 | 2018 | 3050 | 0.040 |
Why?
|
Palmitic Acid | 1 | 2001 | 147 | 0.040 |
Why?
|
Educational Measurement | 1 | 2008 | 1260 | 0.040 |
Why?
|
Crosses, Genetic | 1 | 2001 | 752 | 0.040 |
Why?
|
Oximes | 1 | 2022 | 305 | 0.040 |
Why?
|
Cell Separation | 1 | 2006 | 1718 | 0.040 |
Why?
|
Teaching | 1 | 2008 | 1170 | 0.040 |
Why?
|
Squalene | 1 | 2019 | 36 | 0.040 |
Why?
|
Fatal Outcome | 1 | 2005 | 1836 | 0.040 |
Why?
|
Mouth Neoplasms | 1 | 2005 | 595 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 1 | 2006 | 2586 | 0.040 |
Why?
|
Laparoscopy | 1 | 2011 | 2040 | 0.040 |
Why?
|
Retreatment | 1 | 2021 | 598 | 0.040 |
Why?
|
Amino Acids | 1 | 2006 | 1710 | 0.040 |
Why?
|
Lung | 3 | 2019 | 10063 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2015 | 9527 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2004 | 3546 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2001 | 895 | 0.040 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 227 | 0.040 |
Why?
|
beta-Galactosidase | 1 | 1999 | 573 | 0.040 |
Why?
|
Cell Differentiation | 3 | 2007 | 11642 | 0.040 |
Why?
|
Cisplatin | 1 | 2024 | 1654 | 0.040 |
Why?
|
Cutaneous Fistula | 1 | 1998 | 80 | 0.040 |
Why?
|
Blotting, Western | 2 | 2004 | 5020 | 0.040 |
Why?
|
Gene Targeting | 1 | 2021 | 840 | 0.040 |
Why?
|
Macrophages | 2 | 2018 | 5776 | 0.040 |
Why?
|
Transcription Factors | 1 | 2017 | 12130 | 0.040 |
Why?
|
Intestinal Fistula | 1 | 1998 | 146 | 0.040 |
Why?
|
Receptors, Cell Surface | 1 | 2007 | 2815 | 0.040 |
Why?
|
ROC Curve | 2 | 2018 | 3614 | 0.040 |
Why?
|
Risk Assessment | 4 | 2016 | 24276 | 0.040 |
Why?
|
Bile Duct Neoplasms | 1 | 2003 | 624 | 0.030 |
Why?
|
Ultraviolet Rays | 1 | 2022 | 1099 | 0.030 |
Why?
|
Cohort Studies | 4 | 2023 | 41684 | 0.030 |
Why?
|
Diagnosis, Differential | 3 | 2005 | 12976 | 0.030 |
Why?
|
HIV | 1 | 2004 | 1587 | 0.030 |
Why?
|
Jejunal Diseases | 1 | 1997 | 45 | 0.030 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2000 | 391 | 0.030 |
Why?
|
Calculi | 1 | 1997 | 48 | 0.030 |
Why?
|
Ovarian Neoplasms | 2 | 2012 | 4904 | 0.030 |
Why?
|
Cloning, Molecular | 1 | 2002 | 4163 | 0.030 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1394 | 0.030 |
Why?
|
HIV-1 | 1 | 2014 | 6948 | 0.030 |
Why?
|
Chronic Disease | 3 | 2017 | 9354 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 4342 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1852 | 0.030 |
Why?
|
Surgical Procedures, Operative | 1 | 2008 | 1931 | 0.030 |
Why?
|
HLA-DR Antigens | 1 | 2018 | 608 | 0.030 |
Why?
|
Ileum | 1 | 1998 | 558 | 0.030 |
Why?
|
Pneumonia | 1 | 2008 | 2159 | 0.030 |
Why?
|
Bromodeoxycytidine | 1 | 1975 | 1 | 0.030 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1673 | 0.030 |
Why?
|
Gossypol | 1 | 2015 | 23 | 0.030 |
Why?
|
Ureter | 1 | 1998 | 364 | 0.030 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2019 | 453 | 0.030 |
Why?
|
Mice, SCID | 2 | 2014 | 2626 | 0.030 |
Why?
|
Diverticulum | 1 | 1997 | 137 | 0.030 |
Why?
|
Chills | 1 | 2015 | 17 | 0.030 |
Why?
|
Abdomen, Acute | 1 | 1996 | 122 | 0.030 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 4423 | 0.030 |
Why?
|
Granuloma | 1 | 2017 | 329 | 0.030 |
Why?
|
Proteomics | 1 | 2009 | 3907 | 0.030 |
Why?
|
Peptides | 2 | 2013 | 4338 | 0.030 |
Why?
|
Interleukin-6 | 2 | 2020 | 3227 | 0.030 |
Why?
|
Macrophage Activation | 1 | 2018 | 553 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2001 | 2351 | 0.030 |
Why?
|
Factitious Disorders | 1 | 1995 | 39 | 0.030 |
Why?
|
Advisory Committees | 1 | 2019 | 796 | 0.030 |
Why?
|
Toluidines | 1 | 2014 | 21 | 0.030 |
Why?
|
Crotonates | 1 | 2014 | 21 | 0.030 |
Why?
|
Informed Consent | 1 | 2001 | 1010 | 0.030 |
Why?
|
Butadienes | 1 | 2014 | 107 | 0.030 |
Why?
|
Chromones | 1 | 2014 | 148 | 0.030 |
Why?
|
Rectal Neoplasms | 2 | 2000 | 1183 | 0.030 |
Why?
|
Virus Diseases | 1 | 2000 | 720 | 0.030 |
Why?
|
Leukocyte Transfusion | 1 | 2014 | 58 | 0.030 |
Why?
|
Immunomodulation | 1 | 2018 | 548 | 0.030 |
Why?
|
Risk Factors | 4 | 2016 | 74857 | 0.030 |
Why?
|
Infusion Pumps | 1 | 1995 | 163 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2011 | 20700 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2018 | 1605 | 0.030 |
Why?
|
Graft Rejection | 1 | 2007 | 4504 | 0.030 |
Why?
|
Prostate | 1 | 2002 | 1758 | 0.030 |
Why?
|
Tromethamine | 1 | 1993 | 31 | 0.030 |
Why?
|
Tolmetin | 1 | 1993 | 24 | 0.030 |
Why?
|
Seasons | 1 | 2019 | 1522 | 0.030 |
Why?
|
Wounds, Penetrating | 1 | 1996 | 316 | 0.030 |
Why?
|
Neurotoxicity Syndromes | 1 | 2017 | 302 | 0.030 |
Why?
|
Carcinoma | 1 | 2005 | 2313 | 0.030 |
Why?
|
Endothelium | 1 | 1996 | 768 | 0.030 |
Why?
|
Thoracic Injuries | 1 | 1996 | 288 | 0.030 |
Why?
|
Carcinoma, Endometrioid | 1 | 2016 | 275 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 36548 | 0.030 |
Why?
|
Infection Control | 1 | 2000 | 984 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2009 | 6545 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 1997 | 433 | 0.030 |
Why?
|
Skin | 2 | 2019 | 4482 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2004 | 5300 | 0.030 |
Why?
|
Isoxazoles | 1 | 2014 | 233 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2014 | 14456 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2009 | 8924 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 1995 | 490 | 0.030 |
Why?
|
Protein Binding | 1 | 2005 | 9301 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15403 | 0.030 |
Why?
|
Interferons | 1 | 2016 | 714 | 0.030 |
Why?
|
Conjunctivitis, Allergic | 1 | 1993 | 124 | 0.020 |
Why?
|
Patient Care | 1 | 2018 | 630 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2018 | 1077 | 0.020 |
Why?
|
Receptor, IGF Type 1 | 1 | 2014 | 385 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2005 | 5126 | 0.020 |
Why?
|
Feedback, Physiological | 1 | 2014 | 480 | 0.020 |
Why?
|
Muscle, Smooth | 1 | 1996 | 931 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2001 | 2425 | 0.020 |
Why?
|
Safety | 1 | 1996 | 1157 | 0.020 |
Why?
|
Laparoscopes | 1 | 2011 | 36 | 0.020 |
Why?
|
Xanthine Dehydrogenase | 1 | 2011 | 18 | 0.020 |
Why?
|
Neurologic Examination | 1 | 1995 | 913 | 0.020 |
Why?
|
Morpholines | 1 | 2014 | 584 | 0.020 |
Why?
|
Colectomy | 1 | 1996 | 697 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2009 | 20137 | 0.020 |
Why?
|
Restriction Mapping | 1 | 1991 | 848 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 2002 | 3048 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2011 | 507 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1602 | 0.020 |
Why?
|
Placebos | 2 | 2010 | 1659 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 1991 | 1305 | 0.020 |
Why?
|
Allopurinol | 1 | 2011 | 203 | 0.020 |
Why?
|
Hydrocortisone | 4 | 1987 | 1832 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 1837 | 0.020 |
Why?
|
Child | 6 | 2015 | 80573 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6768 | 0.020 |
Why?
|
Nitriles | 1 | 2014 | 981 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3665 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2018 | 2324 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8724 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2016 | 949 | 0.020 |
Why?
|
beta Catenin | 1 | 2014 | 1047 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 1996 | 1276 | 0.020 |
Why?
|
Pyrazines | 1 | 2014 | 1204 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1638 | 0.020 |
Why?
|
Influenza, Human | 1 | 2019 | 1542 | 0.020 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2000 | 2040 | 0.020 |
Why?
|
Lymphocytes | 3 | 1980 | 2602 | 0.020 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2008 | 147 | 0.020 |
Why?
|
Fever | 1 | 2015 | 1607 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2014 | 1490 | 0.020 |
Why?
|
Antigens | 1 | 2013 | 1437 | 0.020 |
Why?
|
Linear Models | 2 | 2013 | 5873 | 0.020 |
Why?
|
Clonal Anergy | 1 | 2007 | 169 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 2015 | 1411 | 0.020 |
Why?
|
Pemphigus | 1 | 1987 | 107 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 1992 | 1610 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2019 | 4782 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2011 | 1613 | 0.020 |
Why?
|
Plasmids | 1 | 1991 | 2267 | 0.020 |
Why?
|
Liver | 1 | 2002 | 7559 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7237 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2013 | 1756 | 0.020 |
Why?
|
Reference Standards | 1 | 2009 | 1011 | 0.020 |
Why?
|
Models, Genetic | 1 | 2015 | 3448 | 0.020 |
Why?
|
International Cooperation | 1 | 2011 | 1433 | 0.020 |
Why?
|
Amides | 1 | 2008 | 451 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 2877 | 0.020 |
Why?
|
Steroid Hydroxylases | 1 | 1985 | 93 | 0.010 |
Why?
|
Peritoneal Neoplasms | 1 | 2011 | 706 | 0.010 |
Why?
|
Capillaries | 1 | 2008 | 751 | 0.010 |
Why?
|
DNA, Viral | 1 | 1991 | 2200 | 0.010 |
Why?
|
Anti-Retroviral Agents | 1 | 2014 | 1786 | 0.010 |
Why?
|
Adrenal Hyperplasia, Congenital | 1 | 1985 | 94 | 0.010 |
Why?
|
Task Performance and Analysis | 1 | 2008 | 771 | 0.010 |
Why?
|
Odds Ratio | 1 | 2015 | 9657 | 0.010 |
Why?
|
Prednisone | 1 | 1987 | 1566 | 0.010 |
Why?
|
Comorbidity | 2 | 2013 | 10579 | 0.010 |
Why?
|
Alternative Splicing | 1 | 2007 | 1103 | 0.010 |
Why?
|
Myristic Acid | 1 | 2001 | 49 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 1995 | 7119 | 0.010 |
Why?
|
Double-Blind Method | 3 | 2010 | 12426 | 0.010 |
Why?
|
Hypersensitivity, Delayed | 2 | 1992 | 490 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8347 | 0.010 |
Why?
|
DNA Damage | 1 | 2011 | 2463 | 0.010 |
Why?
|
Heterotrimeric GTP-Binding Proteins | 1 | 2001 | 94 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2005 | 1885 | 0.010 |
Why?
|
Uterine Cervicitis | 1 | 2000 | 31 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 2007 | 1416 | 0.010 |
Why?
|
Electroporation | 1 | 2002 | 238 | 0.010 |
Why?
|
src Homology Domains | 1 | 2001 | 361 | 0.010 |
Why?
|
Sarcoma | 1 | 1991 | 1801 | 0.010 |
Why?
|
Dementia | 1 | 1995 | 2741 | 0.010 |
Why?
|
Pregnancy | 1 | 2001 | 30233 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 1998 | 7474 | 0.010 |
Why?
|
COS Cells | 1 | 2001 | 1135 | 0.010 |
Why?
|
Blood Pressure | 1 | 1995 | 8532 | 0.010 |
Why?
|
HLA Antigens | 1 | 1985 | 1338 | 0.010 |
Why?
|
Neoplasm Transplantation | 2 | 1993 | 2010 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2013 | 7600 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 3424 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3238 | 0.010 |
Why?
|
Preoperative Care | 1 | 2007 | 2249 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 2000 | 1695 | 0.010 |
Why?
|
Models, Statistical | 1 | 2011 | 5089 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4249 | 0.010 |
Why?
|
Tyrosine | 1 | 2001 | 1427 | 0.010 |
Why?
|
Cervix Uteri | 1 | 2000 | 575 | 0.010 |
Why?
|
Cytoplasm | 1 | 2001 | 1498 | 0.010 |
Why?
|
Wounds, Stab | 1 | 1996 | 72 | 0.010 |
Why?
|
Postoperative Complications | 1 | 1998 | 15808 | 0.010 |
Why?
|
Blood Transfusion, Autologous | 1 | 1996 | 129 | 0.010 |
Why?
|
Nitroprusside | 1 | 1995 | 271 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2015 | 26381 | 0.010 |
Why?
|
Brain | 1 | 2021 | 27177 | 0.010 |
Why?
|
Child, Preschool | 2 | 2015 | 42511 | 0.010 |
Why?
|
Ketorolac Tromethamine | 1 | 1993 | 21 | 0.010 |
Why?
|
Multiple Trauma | 1 | 1996 | 369 | 0.010 |
Why?
|
Infant | 1 | 2015 | 36427 | 0.010 |
Why?
|
Injury Severity Score | 1 | 1996 | 1049 | 0.010 |
Why?
|
New York | 1 | 1995 | 880 | 0.010 |
Why?
|
Clinical Competence | 1 | 2008 | 4859 | 0.010 |
Why?
|
Ophthalmic Solutions | 1 | 1993 | 312 | 0.010 |
Why?
|
Cell Membrane | 1 | 2001 | 3635 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1996 | 2476 | 0.010 |
Why?
|
Ovalbumin | 1 | 1992 | 674 | 0.010 |
Why?
|
Heart Failure | 1 | 1995 | 11837 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2007 | 7850 | 0.010 |
Why?
|
Phosphorylation | 1 | 2001 | 8292 | 0.010 |
Why?
|
Cognition | 1 | 2008 | 7050 | 0.010 |
Why?
|
Wounds, Gunshot | 1 | 1996 | 586 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2007 | 22228 | 0.000 |
Why?
|
Immunization | 1 | 1992 | 1218 | 0.000 |
Why?
|
17-Hydroxycorticosteroids | 1 | 1987 | 38 | 0.000 |
Why?
|
Dopamine | 1 | 1995 | 1582 | 0.000 |
Why?
|
Radioimmunoassay | 1 | 1987 | 860 | 0.000 |
Why?
|
Equipment Design | 1 | 1995 | 3489 | 0.000 |
Why?
|
Drug Combinations | 1 | 1993 | 2076 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2002 | 12775 | 0.000 |
Why?
|
Prednisolone | 1 | 1987 | 324 | 0.000 |
Why?
|
Macaca mulatta | 1 | 1992 | 2341 | 0.000 |
Why?
|
Brain Diseases | 1 | 1995 | 1552 | 0.000 |
Why?
|
Hemodynamics | 1 | 1995 | 4188 | 0.000 |
Why?
|
Ambulatory Care | 1 | 1995 | 2778 | 0.000 |
Why?
|
Patient Care Team | 1 | 1995 | 2517 | 0.000 |
Why?
|
Boston | 1 | 1996 | 9335 | 0.000 |
Why?
|
Histocompatibility Testing | 1 | 1985 | 726 | 0.000 |
Why?
|
Jews | 1 | 1985 | 359 | 0.000 |
Why?
|
Israel | 1 | 1985 | 729 | 0.000 |
Why?
|
Length of Stay | 1 | 1996 | 6490 | 0.000 |
Why?
|
Depressive Disorder | 1 | 1995 | 3712 | 0.000 |
Why?
|
Referral and Consultation | 1 | 1995 | 3617 | 0.000 |
Why?
|
Puberty | 1 | 1985 | 495 | 0.000 |
Why?
|
Computer Simulation | 1 | 1995 | 6254 | 0.000 |
Why?
|
False Negative Reactions | 1 | 1980 | 570 | 0.000 |
Why?
|
Genetic Linkage | 1 | 1985 | 2342 | 0.000 |
Why?
|
False Positive Reactions | 1 | 1980 | 956 | 0.000 |
Why?
|
Pedigree | 1 | 1985 | 4535 | 0.000 |
Why?
|
Algorithms | 1 | 1995 | 14066 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 1995 | 26290 | 0.000 |
Why?
|
Alzheimer Disease | 1 | 1995 | 8724 | 0.000 |
Why?
|
Hot Temperature | 1 | 1979 | 1440 | 0.000 |
Why?
|
Genotype | 1 | 1985 | 13028 | 0.000 |
Why?
|